Immuneering (IMRX) Projected to Announce Quarterly Earnings on Wednesday

Immuneering (NASDAQ:IMRX) is expected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Immuneering to announce earnings of ($0.29) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 PM ET.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.06). On average, analysts expect Immuneering to post ($1.15) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.

Immuneering Stock Performance

IMRX opened at $3.68 on Wednesday. The company has a market capitalization of $238.32 million, a PE ratio of -3.57 and a beta of 0.49. The stock’s fifty day moving average is $4.22 and its 200-day moving average is $4.79. Immuneering has a one year low of $3.38 and a one year high of $8.48.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IMRX. HC Wainwright reaffirmed a “buy” rating on shares of Immuneering in a research note on Friday. Mizuho set a $11.00 price target on shares of Immuneering in a research report on Thursday, October 29th. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Needham & Company LLC upped their price target on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a report on Monday, July 20th. Finally, Chardan Capital upgraded shares of Immuneering to a “strong-buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immuneering currently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

Key Stories Impacting Immuneering

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating, and Wall Street analysts collectively rate IMRX “Moderate Buy.” Immuneering Stock Rated Moderate Buy by Wall Street Analysts
• Negative Sentiment: HC Wainwright cut its loss-per-share forecasts across several periods. It lowered its Q4 2026 estimate to a loss of $0.39 from $0.32, and its fiscal 2026 estimate to a loss of $1.24 from $1.10. Forecast losses also increased for fiscal 2027–2030, including estimates of $1.78, $1.87, $1.86 and $0.81 per share, respectively. The more pessimistic outlook on future earnings could weigh on investor sentiment. Immuneering Corporation stock information

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering’s lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.